Foley & Hoag’s Bruce Quinn, MD, Ph.D., a national expert on Medicare policy and health reform has offered his thoughts on the FDA’s recent notice of intent to issue draft guidance for regulation of lab-developed tests (LDTs) in a couple of forums recently. Here are the urls:
Dr. Quinn will be discussing the radically changing market for lab test pricing (PAMA 2014 and beyond) at Arrowhead’s 6th Annual Personalized Medicine Conference on October 29-30, 2014 in San Francisco, CA.
An additional highlight of this year’s conference will be a three-way conversation on the different perspectives on pricing and reimbursement of lab tests between the government, diagnostic and other industries, moderated by Dr. Quinn, and featuring:
Louis Jacques, MD, Sr. VP & Chief Clinical Officer, ADVI (formerly the Director, Coverage & Analysis Group at CMS)
Paul Billings, MD, Ph.D., Chief Medical Officer, Omicia (formerly the Chief Medical Officer, Life Technologies, Inc.)
Chris Hall, Chief Commercial Officer, Veracyte
Visit www.personalizedmedicinepartnerships.com for more information.